<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095914</url>
  </required_header>
  <id_info>
    <org_study_id>040280</org_study_id>
    <secondary_id>04-C-0280</secondary_id>
    <secondary_id>ABI-CA019</secondary_id>
    <secondary_id>CDR0000393782</secondary_id>
    <nct_id>NCT00095914</nct_id>
    <nct_alias>NCT00092261</nct_alias>
  </id_info>
  <brief_title>Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>Randomized, Crossover, Pharmacokinetic Study Of Paclitaxel (Taxol) And ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle Paclitaxel) In Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel and ABI-007, work in different ways&#xD;
      to stop tumor cells from dividing so they stop growing or die. Combining paclitaxel with&#xD;
      ABI-007 may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase I trial to study the effectiveness of combining paclitaxel with&#xD;
      ABI-007 in treating patients who have locally advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine whether a change in the formulation alters the pharmacokinetic profile of&#xD;
           paclitaxel in the plasma of patients with incurable locally advanced or metastatic solid&#xD;
           tumors treated with ABI-007 and paclitaxel.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Correlate pharmacokinetic data of this regimen with decrease in the neutrophil count at&#xD;
           nadir in these patients.&#xD;
&#xD;
        -  Determine the intra- and interindividual pharmacokinetic variability of ABI-007 in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine protein binding of paclitaxel via measurement of α-1-acid glycoprotein and&#xD;
           serum albumin levels in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a randomized, pilot study.&#xD;
&#xD;
        -  Courses 1 and 2: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive paclitaxel IV over 3 hours on day 1 and ABI-007 IV over 30&#xD;
                minutes on day 22.&#xD;
&#xD;
             -  Arm II: Patients receive ABI-007 IV over 30 minutes on day 1 and paclitaxel IV over&#xD;
                3 hours on day 22.&#xD;
&#xD;
        -  Courses 3 and beyond: All patients receive ABI-007 IV over 30 minutes on day 1. Courses&#xD;
           repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel albumin-stabilized nanoparticle formulation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant solid tumor&#xD;
&#xD;
               -  Considered incurable&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Likely to be responsive to taxane-based therapy&#xD;
&#xD;
               -  Patients who are refractory to prior paclitaxel are ineligible&#xD;
&#xD;
          -  No symptomatic or untreated brain metastasis or carcinomatous meningitis&#xD;
&#xD;
               -  No patients who are unable to remain free of corticosteroid therapy for &gt; 4 weeks&#xD;
                  due to CNS disease&#xD;
&#xD;
          -  No previously untreated locally advanced breast cancer&#xD;
&#xD;
          -  No hematologic malignancy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  ALT and AST ≤ 1.5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF ≥ 40%&#xD;
&#xD;
          -  No clinical signs or symptoms of heart failure&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
             participation&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biologic composition to paclitaxel (e.g., docetaxel, Cremophor^® EL [CrEL],&#xD;
             polysorbate 80 [Tween 80], or CrEL-containing medications [e.g., cyclosporine])&#xD;
&#xD;
          -  No history of seizure disorder requiring anticonvulsant therapy&#xD;
&#xD;
          -  No active serious infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) during courses 1 and 2&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior hormonal therapy&#xD;
&#xD;
          -  Concurrent luteinizing hormone-releasing hormone agonists for prostate cancer allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 2 weeks since prior drugs, herbal preparations, or dietary supplements known&#xD;
             to influence CYP3A4 (e.g., phenytoin, rifampin, Hypericum perforatum [St. John's&#xD;
             wort], garlic supplements, or grapefruit juice) and/or CYP2C8&#xD;
&#xD;
          -  No concurrent substances known or likely to interfere with the pharmacokinetics of&#xD;
             paclitaxel (e.g., verapamil or cyclosporine)&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William D. Figg, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

